The wide-open field for Trump's next FDA commissioner stems from Marty Makary's May 2026 resignation, which left Kyle Diamantas as acting head while the White House conducted a deliberate search amid competing priorities like food policy reforms and drug approvals. Low probabilities across listed names reflect fragmented early speculation—former commissioner Stephen Hahn and acting official Diamantas bring institutional continuity, Sara Brenner and Grace Graham offer policy and HHS ties, and Brett Giroir adds prior Trump-era experience—yet no candidate has secured decisive White House backing or Senate momentum. Recent finalist reports and confirmation timelines through an election year have kept trader consensus dispersed, with consolidation likely hinging on an official announcement, alignment with administration health goals, or shifts in congressional dynamics.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoStephen Hahn <1%
Sara Brenner <1%
Kyle Diamantas <1%
No announcement by December 31 <1%
$34,838 Wol.
$34,838 Wol.
Dec 30, 2026
Kyle Diamantas
<1%
Stephen Hahn
1%
Brett Giroir
<1%
Grace Graham
<1%
Sara Brenner
1%
No announcement by December 31
<1%
Stephen Hahn <1%
Sara Brenner <1%
Kyle Diamantas <1%
No announcement by December 31 <1%
$34,838 Wol.
$34,838 Wol.
Dec 30, 2026
Kyle Diamantas
$8,320 Wol.
<1%
Stephen Hahn
$4,144 Wol.
1%
Brett Giroir
$5,265 Wol.
<1%
Grace Graham
$6,683 Wol.
<1%
Sara Brenner
$7,418 Wol.
1%
No announcement by December 31
$3,007 Wol.
<1%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The wide-open field for Trump's next FDA commissioner stems from Marty Makary's May 2026 resignation, which left Kyle Diamantas as acting head while the White House conducted a deliberate search amid competing priorities like food policy reforms and drug approvals. Low probabilities across listed names reflect fragmented early speculation—former commissioner Stephen Hahn and acting official Diamantas bring institutional continuity, Sara Brenner and Grace Graham offer policy and HHS ties, and Brett Giroir adds prior Trump-era experience—yet no candidate has secured decisive White House backing or Senate momentum. Recent finalist reports and confirmation timelines through an election year have kept trader consensus dispersed, with consolidation likely hinging on an official announcement, alignment with administration health goals, or shifts in congressional dynamics.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Rynek otwarty: May 12, 2026, 7:59 PM ET
Wolumen
$34,838Data zakończenia
Dec 31, 2026Rynek otwarty
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The wide-open field for Trump's next FDA commissioner stems from Marty Makary's May 2026 resignation, which left Kyle Diamantas as acting head while the White House conducted a deliberate search amid competing priorities like food policy reforms and drug approvals. Low probabilities across listed names reflect fragmented early speculation—former commissioner Stephen Hahn and acting official Diamantas bring institutional continuity, Sara Brenner and Grace Graham offer policy and HHS ties, and Brett Giroir adds prior Trump-era experience—yet no candidate has secured decisive White House backing or Senate momentum. Recent finalist reports and confirmation timelines through an election year have kept trader consensus dispersed, with consolidation likely hinging on an official announcement, alignment with administration health goals, or shifts in congressional dynamics.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Wolumen
$34,838Data zakończenia
Dec 31, 2026Rynek otwarty
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...The wide-open field for Trump's next FDA commissioner stems from Marty Makary's May 2026 resignation, which left Kyle Diamantas as acting head while the White House conducted a deliberate search amid competing priorities like food policy reforms and drug approvals. Low probabilities across listed names reflect fragmented early speculation—former commissioner Stephen Hahn and acting official Diamantas bring institutional continuity, Sara Brenner and Grace Graham offer policy and HHS ties, and Brett Giroir adds prior Trump-era experience—yet no candidate has secured decisive White House backing or Senate momentum. Recent finalist reports and confirmation timelines through an election year have kept trader consensus dispersed, with consolidation likely hinging on an official announcement, alignment with administration health goals, or shifts in congressional dynamics.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania